Breast cancer genetics: What we know and what we need
暂无分享,去创建一个
[1] M. Swift,et al. Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. , 1986, Journal of the National Cancer Institute.
[2] M. Swift,et al. Breast and other cancers in families with ataxia-telangiectasia. , 1987, The New England journal of medicine.
[3] L. Strong,et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.
[4] D Morrell,et al. Incidence of cancer in 161 families affected by ataxia-telangiectasia. , 1991, The New England journal of medicine.
[5] W. McGuire,et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. , 1992, Human pathology.
[6] M. Stratton,et al. A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome , 1992, Nature Genetics.
[7] An association between the risk of cancer and mutations in the HRAS1 minisatellite locus. , 1993 .
[8] D. Easton,et al. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. , 1993, American journal of human genetics.
[9] J. Bringer,et al. Androgen receptor gene mutation in male breast cancer. , 1993, Human molecular genetics.
[10] D. Easton,et al. The genetic epidemiology of BRCA1 , 1994, The Lancet.
[11] D. Easton,et al. The genetic epidemiology of BRCA1. Breast Cancer Linkage Consortium. , 1994, Lancet.
[12] D. Birnbaum,et al. Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression. , 1994, Anticancer research.
[13] Steven E. Bayer,et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.
[14] N. Hynes,et al. The biology of erbB-2/neu/HER-2 and its role in cancer. , 1994, Biochimica et biophysica acta.
[15] D. Easton,et al. Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.
[16] J. Foekens,et al. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. , 1995, Gene.
[17] M. Seller,et al. Unusual case of Smith-Lemli-Opitz syndrome "type II". , 1995, American journal of medical genetics.
[18] D. Easton,et al. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. , 1995, American journal of human genetics.
[19] D. Bentley,et al. Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.
[20] J. Struewing,et al. BRCA1 mutations in young women with breast cancer , 1996, The Lancet.
[21] C. Croce,et al. ATM mutations in cancer families. , 1996, Cancer research.
[22] Julian Peto,et al. Identification of the breast cancer susceptibility gene BRCA2 , 1996, Nature.
[23] M. Stratton,et al. Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus , 1996, Nature Genetics.
[24] I. Verma,et al. Transcriptional activation by BRCA1 , 1996, Nature.
[25] J. Rommens,et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds , 1996, Nature Genetics.
[26] J Isola,et al. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. , 1997, Cancer research.
[27] F. Couch,et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. , 1997, The New England journal of medicine.
[28] M. Lai,et al. A BRCA1 mutant alters G2-M cell cycle control in human mammary epithelial cells. , 1997, Cancer research.
[29] A. Ashworth,et al. Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation , 1997, Nature Genetics.
[30] P. Hartge,et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.
[31] Yonghong Xiao,et al. Association of BRCA1 with Rad51 in Mitotic and Meiotic Cells , 1997, Cell.
[32] G. Eichele,et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2 , 1997, Nature.
[33] Jing Li,et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome , 1997, Nature Genetics.
[34] K. Isselbacher,et al. Heterozygous ATM mutations do not contribute to early onset of breast cancer , 1997, Nature Genetics.
[35] B. Koller,et al. BRCA1 required for transcription-coupled repair of oxidative DNA damage. , 1998, Science.
[36] I. Bleiweiss,et al. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. , 1998, American journal of human genetics.
[37] D J Schaid,et al. Increased Risk for Cancer in Patients with the Peutz-Jeghers Syndrome , 1998, Annals of Internal Medicine.
[38] B. Ponder,et al. Thymic lymphomas in mice with a truncating mutation in Brca2. , 1998, Cancer research.
[39] A. Lindblom,et al. The role of ataxia-telangiectasia heterozygotes in familial breast cancer. , 1998, Cancer research.
[40] J. Isola,et al. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. , 1998, British Journal of Cancer.
[41] D. Berry,et al. Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history. , 1998, Journal of the National Cancer Institute.
[42] L. Holmberg,et al. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] Hui Tian,et al. BRCA1 physically associates with p53 and stimulates its transcriptional activity , 1998, Oncogene.
[44] B. Ponder,et al. Involvement of Brca2 in DNA repair. , 1998, Molecular cell.
[45] J Chang-Claude,et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.
[46] A. Vincent-Salomon,et al. No significant predictive value of c‐ erbB‐2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer , 1998, International journal of cancer.
[47] A. Aurias,et al. Breast cancer risk in ataxia telangiectasia (AT) heterozygotes: haplotype study in French AT families , 1999, British Journal of Cancer.
[48] D. Livingston,et al. BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. , 1999, Cancer research.
[49] C. Wang,et al. Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. , 1999, Science.
[50] H. Inskip,et al. Risk of breast cancer and other cancers in heterozygotes for ataxia-telangiectasia , 1999, British Journal of Cancer.
[51] H. Olsson. Cancer risks in BRCA2 mutation carriers. , 1999, Journal of the National Cancer Institute.
[52] S. Seal,et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. , 1999, Journal of the National Cancer Institute.
[53] C. Mathew,et al. Identification of germline missense mutations and rare allelic variants in the ATM gene in early‐onset breast cancer , 1999, Genes, chromosomes & cancer.
[54] W. Foulkes,et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. , 1999, Journal of the National Cancer Institute.
[55] S. Elledge,et al. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. , 1999, Science.
[56] L. Kruglyak. Prospects for whole-genome linkage disequilibrium mapping of common disease genes , 1999, Nature Genetics.
[57] M B Daly,et al. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. , 1999, American journal of human genetics.
[58] Nazneen,et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. , 1999, Journal of the National Cancer Institute.
[59] P. Lønning,et al. Screening breast cancer patients for Norwegian ATM mutations , 2000, British Journal of Cancer.
[60] S. Seal,et al. BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[61] Jong-Soo Lee,et al. hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response , 2000, Nature.
[62] D. Livingston,et al. In search of the tumour-suppressor functions of BRCA1 and BRCA2 , 2000, Nature.
[63] J. Klijn,et al. ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. , 2000, American journal of human genetics.
[64] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[65] K. Seibert,et al. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. , 2000, Cancer research.
[66] Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases , 2000 .
[67] R A Irvine,et al. Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor. , 2000, Cancer research.
[68] E. Gillanders,et al. Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[69] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[70] M. Stratton,et al. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[71] T. Rebbeck,et al. Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] J. Peto,et al. High constant incidence in twins and other relatives of women with breast cancer , 2000, Nature Genetics.
[73] J. Sudbø,et al. Gene-expression profiles in hereditary breast cancer. , 2001, The New England journal of medicine.
[74] K Nasmyth,et al. Splitting the chromosome: cutting the ties that bind sister chromatids. , 2000, Novartis Foundation symposium.